1. In Vivo
  2. >>Market Intelligence

Investment Outlook For Cell And Gene Therapies Is Cautiously Optimistic

Cell And Gene Therapy Developers Raised $13.3bn In Financing In 2018

 
• By Amanda Micklus

Investors at Alliance for Regenerative Medicine’s Investor Day in March 2019 were bullish on cell and gene therapies, but some worry about the market overcrowding.

Cell and gene therapies are coming into their own. Within the last two years there have been five first-time regulatory approvals worldwide, and a handful – including Novartis AG’s Zolgensma (onasemnogene abeparvovec) and bluebird bio Inc.’s LentiGlobin (human beta-globin) – are currently being reviewed in the US and EU, respectively, and potentially on track for approvals later in 2019.

For those already on the market, novel payment mechanisms, such as installment plans tied to efficacy, have emerged, as manufacturers...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Intelligence

By The Numbers: Phase III Trials In China Skyrocket While Phase I Falls To Earth

 
• By Mainbayar Badarch

China has rapidly expanded its clinical trial footprint since 2015, driven by regulatory reforms and increased investment in pharma R&D. By 2023, it matched the US in trial volume. Oncology leads, but biologics are leading in momentum.

Podcast: Astellas SVP On Doubling Down On Gene Therapy Despite Industry Headwinds

 
• By David Wild

Richard Wilson, SVP and primary focus lead for genetic regulation at Astellas, talks with In Vivo about the company's commitment to AAV as a gene therapy delivery vehicle, recent company investments and the regulatory environment under Trump's FDA.

PBMs Tighten The Reins: Value Becomes The New Access Gatekeeper

 
• By Andrew Cox

Facing rising costs and tighter regulations, PBMs and insurers are accelerating the shift to value-based drug coverage, demanding stronger proof of therapeutic and economic benefit from pharma.

Financing Quarterly Statistics, Q2 2025

 
• By Deanna Kamienski and Maureen Riordan

During Q2, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $2.7bn; while in vitro diagnostic firms and research tools players raised $1.7bn

More from In Vivo